


## Phenylephrine-2,4,6-d<sub>3</sub> hydrochloride

<b>Cat. No.:</b>	HY-B0471S1
<b>CAS No.:</b>	1276197-50-2
<b>Molecular Formula:</b>	C <sub>9</sub> H <sub>11</sub> D <sub>3</sub> ClNO <sub>2</sub>
<b>Molecular Weight:</b>	206.68
<b>Target:</b>	Adrenergic Receptor; Endogenous Metabolite
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling; Metabolic Enzyme/Protease
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 125 mg/mL (604.80 mM; Need ultrasonic)					
	DMSO : 50 mg/mL (241.92 mM; Need ultrasonic)					
	<b>Preparing Stock Solutions</b>	<b>Solvent</b>	<b>Mass</b>	<b>1 mg</b>	<b>5 mg</b>	<b>10 mg</b>
		<b>Concentration</b>				
		<b>1 mM</b>		4.8384 mL	24.1920 mL	48.3840 mL
<b>5 mM</b>			0.9677 mL	4.8384 mL	9.6768 mL	
	<b>10 mM</b>		0.4838 mL	2.4192 mL	4.8384 mL	
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 1.25 mg/mL (6.05 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 1.25 mg/mL (6.05 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 1.25 mg/mL (6.05 mM); Clear solution					

### BIOLOGICAL ACTIVITY

<b>Description</b>	Phenylephrine-2,4,6-d <sub>3</sub> (hydrochloride) is the deuterium labeled Phenylephrine hydrochloride. (R)-(-)-Phenylephrine hydrochloride is a selective α <sub>1</sub> -adrenoceptor agonist with pK <sub>i</sub> s of 5.86, 4.87 and 4.70 for α <sub>1D</sub> , α <sub>1B</sub> and α <sub>1A</sub> receptors respectively.
<b>In Vitro</b>	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-216.
- [2]. Ford AP, et al. Pharmacological pleiotropism of the human recombinant alpha1A-adrenoceptor: implications for alpha1-adrenoceptor classification. *Br J Pharmacol.* 1997 Jul;121(6):1127-35.
- [3]. Minneman KP, et al. Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes. *Mol Pharmacol.* 1994 Nov;46(5):929-36.
- [4]. Wang J, et al. Phenylephrine promotes cardiac fibroblast proliferation through calcineurin-NFAT pathway. *Front Biosci (Landmark Ed).* 2016 Jan 1;21:502-13.
- [5]. Lazou A, et al. Activation of mitogen-activated protein kinases (p38-MAPKs, SAPKs/JNKs and ERKs) by the G-protein-coupled receptor agonist phenylephrine in the perfused rat heart. *Biochem J.* 1998 Jun 1;332 ( Pt 2):459-65.
- [6]. Li NJ, et al. Effect of phenylephrine on alveolar fluid clearance in ventilator-induced lung injury. *Chin Med Sci J.* 2013 Mar;28(1):1-6.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA